A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The OReO study will be a Phase IIIb, randomised, double-blind, placebo-controlled, multicentre study to assess the efficacy and tolerability of Olaparib retreatment, versus matching placebo, in non-mucinous epithelial ovarian cancer (EOC) patients (including patients with primary peritoneal and/or fallopian tube cancer)
Epistemonikos ID: b5b5251dbca0be3e9745973d4a7d6d01349ccf46
First added on: May 20, 2024